Product news

Share this article:

The FDA has approved UCB and Sanofi-Aventis' NDA for Xyzal (levocetirizine dihydrochloride) 0.5 mg/ml oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria. Xyzal tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older.

King Pharmaceuticals announced its has launched a tablet version of its ACE inhibitor
Altace (ramipril). The company will continue to make available Altace capsules.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.